FAUN 264G
Alternative Names: FAUN-264-GLatest Information Update: 22 Nov 2025
At a glance
- Originator Fauna Bio
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Retinal disorders
Most Recent Events
- 28 Oct 2025 Preclinical trials in Retinal disorders in USA (unspecified route), before October 2025 (Fauna Bio Pipeline, October 2025)